- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canadian Cannabis Stocks Valuation is ‘Absurd,’ Says CEO
During a talk to investors at the Arcview Investor Forum in Las Vegas on Monday, Abner Kurtin, CEO of Ascend Wellness, shared his views on the current market and where investors may find real value.
On Monday (November 12), the first day of activities at the Arcview Investor Forum for cannabis investors kicked off in Las Vegas, and the Investing News Network (INN) was on the floor attending a variety of panel discussions.
In particular, one panel with Abner Kurtin, CEO of Ascend Wellness, gave a talk on where the real money is for investors. Kurtin, who joined the cannabis industry from a hedge fund background, said while investors are excited to capture the cannabis opportunity problems arise with such a specific focus.
“Historically when investors chase an industry opportunity, they lose all their money,” he said, pointing to investing failures such as online companies.
Kurtin explained no one really knows which companies today will become the next Google (NASDAQ:GOOGL).
Current market overview
When discussing Canadian licensed producers (LPs), which have dominated much of the conversation on public marijuana options, Kurtin said the valuations for these were “absurd.”
The executive compared Canadian LPs to disk drive manufacturers in the ‘80s, which he said got funded to obtain a 10 percent of the market share in the space.
“We’re going to fund infinite capital at a business and in a commodity agriculture product and it’s going to stay at $7 a gram and we’re all going to get rich. It does not work—ever.”
In a presenting slide on the Canadian market, Kurtin said it has too much capital and a population that can’t consume the amount of cannabis being produced.
Kurtin said the valuation seen for Tilray (NASDAQ:TLRY), while “crazy,” shows people want to be involved in the sector and will pay whatever price needed.
Alternatively, on US cannabis companies, the executive added he thinks they are fully valued.
Dangers of shorting
The executive went on to explain shorting cannabis stocks, a tactic that has become more popular with new research reports, is not the right answer at the moment.
In his view, US states legislation on cannabis will pass this year, which could cause a hit on short positions. Kurtin also said financial institutions such as Goldman Sachs are coming for the sector.
“This is a very dangerous time to be short,” he said.
Investor takeaway
Kurtin recommended integrated vertical business that operate on licenses and will be capable to have high volume retail.
The executive pointed investors to private US companies as the potential money makers to be driven into the public sector.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.